Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Qudexy XR Extended-Release capsules).
Topiramate Extended-Release capsule is indicated to prevent and control seizures in people with epilepsy. It may also be used to prevent migraine headaches. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Topiramate Extended-Release capsule had annual sales of $68.8 million in the United States according to IQVIA data (IQVIA MAT September 2022). The group now has 335 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04 (as of September 30, 2022).
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
